My cart
In the shopping cart is not goods, to choose and buy!
  • Product Name
  • Size
  • Quantity
  • Amount
    Selected items : 0 pieces Total : CHECK OUT()
    MLN0905
    MLN0905

    Price:
    Market Price:

    This product is for research use only, not for human use. We do not sell to patients.
    Number: - + Pieces(InventoryPieces)
    InvivoChem Cat #: V1578
    CAS #: 1228960-69-7Purity ≥98%

    Description: MLN0905 is a novel, potent and selective small-molecule inhibitor of PLK1 with IC50 of 2 nM. MLN0905 inhibits cell proliferation in a broad range of human tumor cells including DLBCL cell lines. PLK1 inhibition leads to pharmacodynamic pHisH3 modulation and significant antitumor activity in multiple DLBCL models. These data strongly suggest evaluating PLK1 inhibitors as DLBCL anticancer agents in the clinic.

    References: J Med Chem. 2012 Jan 12;55(1):197-208; Mol Cancer Ther. 2012 Sep;11(9):2045-53.

    Customer Validation
    Official Supplier of
    • VE
    • OF
    • YALE
    • hhmi
    • 香港大学
    Related Products
    Publications Citing InvivoChem Products
    • Physicochemical and Storage Information
    • Protocol
    • Quality Control Documentation
    • Related Biological Data
    • Customer Review
    Molecular Weight (MW)486.56
    FormulaC24H25F3N6S
    CAS No.1228960-69-7
    Storage-20℃ for 3 years in powder form
    -80℃ for 2 years in solvent
    Solubility (In vitro)DMSO: 97 mg/mL (199.4 mM)
    Water:<1 mg/mL
    Ethanol: <1 mg/mL
    Other infoChemical Name: 2-((5-(3-(dimethylamino)propyl)-2-methylpyridin-3-yl)amino)-9-(trifluoromethyl)-5H-benzo[b]pyrimido[4,5-d]azepine-6(7H)-thione
    InChi Key: CODBZFJPKJDNDT-UHFFFAOYSA-N
    InChi Code: InChI=1S/C24H25F3N6S/c1-14-19(9-15(12-28-14)5-4-8-33(2)3)31-23-29-13-16-10-21(34)30-20-11-17(24(25,26)27)6-7-18(20)22(16)32-23/h6-7,9,11-13H,4-5,8,10H2,1-3H3,(H,30,34)(H,29,31,32)
    SMILES Code: S=C1CC2=CN=C(NC3=CC(CCCN(C)C)=CN=C3C)N=C2C4=CC=C(C(F)(F)F)C=C4N1
    SynonymsPLK1 inhibitor; MLN0905; MLN 0905; MLN-0905


    • Molarity Calculator
    • Dilution Calculator
    • The molarity calculator equation

      Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

      • Mass
      • Concentration
      • Volume
      • Molecular Weight *
      • =
      • ×
      • ×
    • The dilution calculator equation

      Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

      This equation is commonly abbreviated as: C1V1 = C2V2

      • Concentration (start)
      • ×
      • Volume (start)
      • =
      • Concentration (final)
      • ×
      • Volume (final)
      • ×
      • =
      • ×
      • C1
      •  
      • V1
      •  
      • C2
      •  
      • V2
    In Vitro

    In vitro activity: MLN0905 is a potent inhibitor of PLK1 with IC50 of 2 nM. MLN0905 inhibits cell mitosis with EC50 of 9 nM. MLN0905 inhibits Cdc25C-T96 phosphorylation, a direct readout of PLK1 inhibition with EC50 of 29 nM. MLN0905 inhibits HT-29 viability with LD50 of 22 nM. MLN0905 possesses reasonable selectivity against a panel of 359 kinases. MLN0905 inhibits a panel of lymphoma cells viability with IC50 of 3 – 24 nM.


    Kinase Assay: The human PLK1 enzymatic reaction totaling 30μL contained 50 mM Tris-HCl (pH 8.0), 10 mM MgCl2, 0.02% BSA, 10% glycerol, 1 mM DTT, 100 mM NaCl, 3.3% DMSO, 8 μM ATP, 0.2μCi [γ- 33 P]-ATP, 4μM peptide substrate (Biotin-AHX-LDETGHLDSSGLQEVHLA-CONH2), and 10 nM recombinant human PLK1[2–369]T210D. The enzymatic reaction mixture, with or without PLK inhibitors, is incubated for 2.5 h at 30℃before termination with 20μL of 150 mM EDTA. Then 25μL of the stopped enzyme reaction mixture is transferred to a 384-well streptavidin coated Image FlashPlate and incubated at room temperature for 3 h. The Image Flash Plate wells are washed three times with 0.02% Tween-20 and then read on the Perkin-Elmer Viewlux.


    Cell Assay: MLN0905 is a selective PLK1 inhibitor and has similar effect as RNAi hnockdown. When tested with HT-29 cells, MLN0905 treatment significantly increased pHisH3 expression which indicated that cells were arrested in G2/M phase by inhibiting PLK1 expression.

    In VivoNude mice bearing HT-29 xenografts administered with MLN0905 (6.25 mg/Kg - 50 mg/Kg, p.o.) shows dose-dependent pharmacodynamic responses (48 hours after treatment). OCI LY-19-Luc tumor bearing mice administered with MLN0905 (3.12 mg/Kg – 6.25 mg/Kg, p.o.) shows significant pharmacodynamic responses amd peaks at 8 hours after treatment. MLN0905 shows antitumor efficacy in treatment with OCI LY-19-Luc xenografts bearing scid mice for 21 days. The T/C of 6.25 mg/Kg daily group is 0.15.
    Animal model Mice
    Formulation & Dosage 6.25 mg/Kg - 50 mg/Kg, p.o.
    ReferencesJ Med Chem. 2012 Jan 12;55(1):197-208; Mol Cancer Ther. 2012 Sep;11(9):2045-53.


    These protocols are for reference only. InvivoChem does not independently validate these methods.

    MLN0905

    MLN0905 induces a significant antitumor response in mice bearing disseminated (human) OCI LY-19-Luc lymphoma disease.

    MLN0905

    pHisH3 was used as a biomarker to determine the level of mitotic arrest in OCI LY-19-Luc xenograft tumors.  2012 Sep;11(9):2045-53.

     

    MLN0905

    MLN0905, a small-molecule inhibitor of PLK1, phenocopies the effects of PLK1 knockdown using RNAi in HT-29 cells. 

    MLN0905

    MLN0905 induces a significant antitumor response in a primary human lymphoma model (PHTX-22L).  2012 Sep;11(9):2045-53.

     

    MLN0905

    MLN0905 and rituximab yield a synergistic antitumor response in a disseminated xenograft model of human lymphoma (OCI LY-19-Luc).

    MLN0905

    Evaluating the effect of dosing schedule versus antitumor effect with MLN0905 in the OCI LY-10 subcutaneous tumor model.  2012 Sep;11(9):2045-53.


    评论

      Home Prev Next Last page / pices

      发评论

      ×
      Your information is safe with us. * Required Fields.
      Products are for research use only;  We do not sell to patients
      Tel: 1-708-310-1919
      Fax: 1-708-557-7486
      Subscribe to our E-newsletter
      • Name*
      • *
      • E-mail*
      • *
      • instructions:
      • *
      Copyright 2020 InvivoChem LLC | All Rights Reserved
      prompt
      Do you confirm the receipt?